Skip to main content
    I

    Inovio Pharmaceuticals Inc (INO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    -0.03 (-2.10%)

    Market Cap: $267.85M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inovio Pharmaceuticals Inc (INO) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Inovio Pharmaceuticals (INO) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Inovio Pharmaceuticals reported EPS of -$0.23, below the -$0.20 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -14.64%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.20
    Range-$0.22 - -$0.19
    4 analysts
    Revenue Consensus
    $673.34K
    RangeN/A
    4 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.17
    Range-$0.22 - -$0.12
    2 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.19+8.1%
    60d ago-$0.18+2.9%
    30d ago-$0.18+2.9%
    7d ago-$0.18+2.9%
    Current-$0.17
    Revenue Consensus
    $7.00M
    Range$6.00M - $8.00M
    2 analysts

    Next Report

    INO has an expected report date of Mar 10, 2027.

    INO Earnings Call

    The latest INO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, INO beat 18 and missed 22. The widest gap in the table came in the quarter ended Jun 30, 2020, when EPS landed 393.07% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.23-$0.20-$0.20 - -$0.19-15.00%MissN/A22 up, 0 downNov 10, 2026$298901
    Jun 30, 2026-$0.07-$0.25-$0.26 - -$0.23+72.00%BeatN/A22 up, 0 downAug 12, 2026N/A
    Mar 31, 2026-$0.31-$0.33-$0.38 - -$0.29+6.06%BeatN/A32 up, 1 downMay 13, 2026N/A
    Dec 31, 2025-$0.28-$0.35-$0.38 - -$0.28+19.59%BeatN/A44 up, 0 downMar 12, 2026N/A
    Sep 30, 2025-$0.87-$0.48-$0.58 - -$0.40-81.25%MissN/A54 up, 1 downNov 10, 2025N/A
    Jun 30, 2025-$0.61-$0.62-$0.69 - -$0.53+1.61%BeatN/A53 up, 0 downAug 12, 2025N/A
    Mar 31, 2025-$0.51-$0.74-$0.84 - -$0.65+31.08%BeatN/A40 up, 1 downMay 13, 2025$65343
    Dec 31, 2024-$0.60-$0.83-$1.04 - -$0.62+27.88%BeatN/A52 up, 0 downMar 18, 2025$116994
    Sep 30, 2024-$0.89-$1.13-$1.24 - -$0.94+21.24%BeatN/A60 up, 0 downNov 14, 2024N/A
    Jun 30, 2024-$1.19-$1.10-$1.28 - -$0.94-8.18%MissN/A60 up, 0 downAug 8, 2024$100762
    Mar 31, 2024-$1.31-$0.99-$1.17 - -$0.86-32.32%MissN/A50 up, 0 downMay 13, 2024N/A
    Dec 31, 2023-$1.12-$1.27-$1.83 - -$0.96+11.81%BeatN/A40 up, 0 downMar 6, 2024$102650
    Sep 30, 2023-$1.56-$1.50-$1.56 - -$1.44-4.00%MissN/A30 up, 0 downNov 9, 2023$388446
    Jun 30, 2023-$1.56-$1.72-$1.92 - -$1.56+9.30%BeatN/A40 up, 0 downAug 9, 2023$225971
    Mar 31, 2023-$1.92-$1.80-$1.92 - -$1.56-6.67%MissN/A40 up, 0 downMay 10, 2023$114943
    Dec 31, 2022-$0.21-$0.17-$0.19 - -$0.14-23.53%MissN/A50 up, 0 downMar 1, 2023$909061
    Sep 30, 2022-$1.80-$3.27-$4.32 - -$2.64+44.95%BeatN/A70 up, 0 downNov 8, 2022$9.15M
    Jun 30, 2022-$5.52-$3.52-$4.44 - -$2.88-56.82%MissN/A60 up, 1 downAug 9, 2022N/A
    Mar 31, 2022-$4.32-$3.93-$5.88 - -$3.00-9.92%MissN/A60 up, 0 downMay 10, 2022$199074
    Dec 31, 2021-$0.50-$0.32-$0.44 - -$0.17-56.25%MissN/A9N/AMar 1, 2022$1.22M
    Sep 30, 2021-$3.48-$3.62-$5.04 - -$2.76+3.87%BeatN/A103 up, 0 downNov 9, 2021N/A
    Jun 30, 2021-$4.68-$3.06-$4.08 - -$2.16-52.94%MissN/A10N/AAug 9, 2021$272824
    Mar 31, 2021-$3.24-$2.34-$2.52 - -$1.92-38.46%MissN/A7N/AMay 10, 2021$281556
    Dec 31, 2020-$0.14-$0.22-$0.29 - -$0.17+36.36%BeatN/A9N/AMar 1, 2021$5.58M
    Sep 30, 2020-$2.76-$2.30-$3.12 - -$1.20-20.00%MissN/A8N/ANov 9, 2020$236178
    Jun 30, 2020-$9.96-$2.02-$2.16 - -$1.92-393.07%MissN/A8N/AAug 10, 2020$267187
    Mar 31, 2020-$3.12-$2.85-$3.48 - -$2.16-9.47%MissN/A6N/AMay 11, 2020$1.33M
    Dec 31, 2019-$0.38-$0.24-$0.25 - -$0.23-58.33%MissN/A6N/AMar 12, 2020$279489
    Sep 30, 2019-$2.76-$3.07-$3.60 - -$2.52+10.10%BeatN/A7N/ANov 12, 2019$866863
    Jun 30, 2019-$3.60-$3.46-$3.72 - -$2.16-4.05%MissN/A8N/AAug 8, 2019$135673
    Mar 31, 2019-$3.60-$3.06-$3.84 - -$1.68-17.65%MissN/A8N/AMay 9, 2019$2.83M
    Dec 31, 2018-$0.35-$0.28-$0.31 - -$0.21-25.00%MissN/A5N/AMar 12, 2019$2.50M
    Sep 30, 2018-$3.24-$3.54-$4.08 - -$2.76+8.47%BeatN/A6N/ANov 8, 2018$2.00M
    Jun 30, 2018-$0.84-$2.34-$4.32 - -$0.12+64.10%BeatN/A5N/AAug 7, 2018$24.45M
    Mar 31, 2018-$4.32-$3.24-$3.24 - -$0.24-33.33%MissN/A5N/AMay 9, 2018$1.53M
    Dec 31, 2017-$0.23-$0.30-$0.33 - -$0.26+23.33%BeatN/A5N/AMar 14, 2018$8.79M
    Sep 30, 2017-$4.68-$3.05-$4.20 - -$1.56-53.44%MissN/A7N/ANov 8, 2017$2.64M
    Jun 30, 2017-$1.56-$2.52-$4.20 - -$0.12+38.10%BeatN/A5N/AAug 8, 2017$20.41M
    Mar 31, 2017-$3.72-$3.75N/A+0.80%BeatN/AN/AN/AMay 10, 2017$10.38M
    Dec 31, 2016-$0.35-$0.30N/A-16.67%MissN/AN/AN/AMar 15, 2017$8.51M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.27, after -$3.99 the year before. It was -$8.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.27N/A
    Dec 31, 2024-$3.99N/A
    Dec 31, 2023-$6.16N/A
    Dec 31, 2022-$11.85N/A
    Dec 31, 2021-$11.90N/A
    Dec 31, 2020-$15.98N/A
    Dec 31, 2019-$10.34N/A
    Dec 31, 2018-$8.75N/A
    Dec 31, 2017-$10.19N/A
    Dec 31, 2016-$8.15N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,7019
    2026Q2Jun 30, 20263,4538
    2026Q1Mar 31, 20264,38811
    2025Q4Dec 31, 20254,38610
    2025Q3Sep 30, 20254,2339
    2025Q2Jun 30, 20255,64413
    2025Q1Mar 31, 20255,02712
    2024Q4Dec 31, 20247,35711

    2026Q3 Earnings Call

    Opening remarks

    Jennie Willson Investor Relations Good afternoon, and thank you for joining the Inovio Third Quarter 2026 Financial Results Conference Call. Joining me on today's call are Dr. Jacqui Shea, President and Chief Executive Officer; Dr. Mike Sumner, Chief Medical Officer; Steven Egge, Chief Commercial Officer; and Peter Kies, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended September 30, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment. Before we begin, I'd like to remind you that we will be making certain forward-looking statements as outlined in this slide, including, but not limited to, our ability to obtain and maintain regulatory approval of our product candidates; the design and timing of our planned confirmatory study; the potential benefits of VOCERYQ and its potential to become a product preferred by patients and their physicians; our commercial launch plans and strategy, including anticipated cash runway, cash burn and timing of product revenues; and our plans to expand VOCERYQ into additional indications and geographies and advance our broader pipeline. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which, under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed verbally by the company or in this afternoon's press release. This call is being webcast live, and a link can be found on our website, ir.inovio.com. A replay will be made available shortly after this call is concluded. I will now turn the call over to Inovio's President and CEO, Dr. Jacqui Shea.

    Jacqueline Shea President and Chief Executive Officer Good afternoon, and thank you to everyone for joining. I'd like to start today's call by highlighting the recent FDA approval of VOCERYQ, formerly known as INO-3107, under the Accelerated Approval Program as a new nonsurgical treatment option to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, or RRP. In the press release it issued, the FDA stated that VOCERYQ was a groundbreaking therapy and that its approval represented a meaningful scientific breakthrough by offering patients a plasmid DNA-based immunotherapy that harnesses the body's own immune system to fight the underlying cause of RRP. The accelerated approval for VOCERYQ and the broad indication included in its label for adults with RRP are an acknowledgment of the significant unmet need for nonsurgical treatment options for RRP and the potential therapeutic benefit that VOCERYQ can provide.

    Frequently Asked Questions About INO

    When is Inovio Pharmaceuticals's next earnings date?

    Inovio Pharmaceuticals's next earnings report is expected for Mar 10, 2027.

    Did INO beat earnings estimates last quarter?

    No. Inovio Pharmaceuticals reported EPS of -$0.23 for the quarter ended Sep 30, 2026, below the -$0.20 estimate by 15.00%.

    What EPS do analysts expect from INO next quarter?

    The consensus EPS estimate for Inovio Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.20 from 4 analysts, with estimates from -$0.22 to -$0.19.

    How often does INO beat earnings estimates?

    Inovio Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +7.75%.